CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and China in 2020 QIAGEN ...
Enabling highly automated screening solution for latent tuberculosis in all throughput segments Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current ...
Qiagen N.V., a leading global provider, and DiaSorin announced a groundbreaking partnership that plans to add Qiagen’s QuantiFERON-TB diagnostic test to the menu of DiaSorin’s LIAISON family of fully ...
QIAGEN N.V. QGEN announced that it partnered with Tecan Group AG. to enhance the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test. Notably, Tecan has a strong grip on ...
Germantown, Md. & HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback